New trial
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
- Trial ID
- NCT05673200 on ClinicalTrials.gov
- Cancer type
- Breast Cancer
- Location
- 10 Locations
- Published in
- New in Oncology - May 29, 2025
The NCI trial is evaluating ASTX727—combining decitabine (a hypomethylation agent) with cedazuridine (a cytidine deaminase inhibitor)—in combination with paclitaxel and pembrolizumab across 1st to 4th line metastatic TNBC settings to determine safety, optimal dosing, and potential efficacy.
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer